Option chain shows key data for Onconetix's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Onconetix.

Onconetix (NASDAQ:ONCO) Stock, Option Chain

Onconetix

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Recent Gains

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket

wall street chart shutter2

Equities

Eurozone

Commodities

Intraday Update

ACAD

COCP

SGMO

Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

Crude Oil 6- logo

Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet

Onconetix Inc

ONCO-INNOVATIONS LTD by ONCO-INNOVATIONS LTD.

OncoCyte Corp

ONCOSEC MEDICAL INC NEW by OncoSec Medical Incorporated

OncoSec Medical Inc

OncoSil Medical Ltd

ONCOVISTA INNVTVE THERPS by OncoVista Innovative Therapies, Inc.

OncoVista Innovative Therapies Inc

ONCOLOGIX TECH INC by Oncologix Tech, Inc.

Oncologix Tech Inc

ONCOLOGY PHARMA INC by Oncology Pharma Inc.

Oncology Pharma Inc

Oncolytics Biotech Inc

Oncopeptides AB

Oncorus Inc rdinary Shares

ONCOTELIC THERAPEUTCS INC by Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc

Press Releases

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

ENTO

VRNA

Aditxt

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Alzamend Neuro

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Entero Therapeutics

Genprex

GRI Bio

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Oragenics

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Plus Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Synaptogenix

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Theriva Biologics

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Onconetix

Onconetix (ONCO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga